Trial Profile

A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 27 May 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rifaximin (Primary) ; Lactulose
Indications Hepatic encephalopathy
Focus Therapeutic Use

Most Recent Events

01 Mar 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
18 Aug 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2016, as reported by ClinicalTrials.gov.
18 Aug 2015 Status changed from recruiting to not yet recruiting, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com